Risk Signature in the Blood – Long-standing Lab Work Makes Possible What Clinics Wish for MS Therapy
Cells-in-Motion Podcast | Episode 12
In the autoimmune disease multiple sclerosis (MS), the immune system attacks endogenous nerve fibres and destroys their protective layer, which may cause something called “MS relapses”, often resulting in impaired vision or palsy. Nowadays though, these MS relapses can be suppressed by a particular medicine. But in rare cases, death can occur as a result of one severe side effect: brain inflammation.
Multiple sclerosis is a focus of the Department of General Neurology at the University Hospital Münster, and its physicians are working on ways to reveal an MS patient’s risk of brain inflammation before they take this medicine. According to physician Prof. Heinz Wiendl, information about how high the risk of brain inflammation is for an individual patient can be provided by a biomarker. Dr. Nicholas Schwab and his team had been searching for such a biomarker, and they finally found one. However, until the biomarker finally becomes part of a doctor’s checklist, it must first undergo years of laboratory research at both the federal and the EU-level.